+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P02317(VNN2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

VNN2 (Vanin-2) is a glycosylphosphatidylinositol (GPI)-anchored membrane protein belonging to the vanin family, which includes VNN1 and VNN3. It is encoded by the *VNN2* gene and is highly expressed in tissues such as the intestine, liver, and kidney. Functionally, VNN2 exhibits pantetheinase activity, catalyzing the hydrolysis of pantetheine to produce cysteamine and pantothenic acid (vitamin B5). This enzymatic role links VNN2 to cellular metabolism, oxidative stress responses, and inflammation.

VNN2 is implicated in innate immunity, particularly in regulating leukocyte migration and adhesion during inflammatory processes. It interacts with integrins and modulates extracellular matrix remodeling, influencing tissue repair and inflammatory diseases. Research highlights its association with pathologies like inflammatory bowel disease (IBD), atherosclerosis, and cancer. In cancer, VNN2 overexpression has been observed in certain malignancies, potentially contributing to tumor progression and metastasis via pathways involving oxidative signaling and immune evasion.

Antibodies targeting VNN2 are critical tools for studying its expression, localization, and function. They enable applications such as immunohistochemistry, flow cytometry, and Western blotting, aiding in the exploration of VNN2's role in disease mechanisms and its potential as a therapeutic target or biomarker. Recent studies also investigate its utility in modulating metabolic-inflammatory crosstalk, emphasizing its dual role in health and disease.